BioCentury-BayHelix East-West Biopharma Summit - Award Winners

For several years, BayHelix has hosted the China Healthcare Awards, celebrating outstanding individuals and companies for their achievement and contribution to the local healthcare ecosystem. In 2022, BayHelix and BioCentury will jointly host the BioCentury-BayHelix East-West Biopharma Summit (Nov. 14-16, Grand Bay Hotel San Francisco), and will present the awards in five categories: R&D Achievement of the Year; Deal of the Year; Commercial Achievement of the Year; Company of the Year; and Woman Leader of the Year. Congratulations to the 2022 BayHelix Award Winners listed below.


R&D Achievement of the Year | Immune-Onc Therapeutics

Recognizing a scientific discovery in China with direct impact to drug and/or medtech R&D or a significant achievement in pharmaceutical and/or medtech development milestones.


Immune-Onc Therapeutics

Developing first-in-class myeloid checkpoint inhibitors for cancer patients, including two programs in the clinic, plus deals with BeiGene and Regeneron to evaluate its compounds in combination with anti-PD-1 antibodies.

Deal of the Year | Turning Point Therapeutics /
Bristol Myers Squibb 

Recognizing a groundbreaking pharmaceutical and/or medtech fund-raising, collaboration, technology transfer, licensing, M&A or joint venture that involves a Chinese entity, either within China or cross-border.


Turning Point Therapeutics and Bristol Myers Squibb

The $4.1B acquisition of Turning Point gave BMS a pipeline of five oncology clinical candidates, topped by repotrectinib, which reported a 79% ORR in ROS1-positive NSCLC patients in a recent Phase I/II study. The takeout represented a 122% premium over prior-day closing price of Turning Point.

Commercial Achievement of the Year | Legend Biotech

Recognizing a creative model that delivered superior value to patients/payers and commercial success.


Legend Biotech

In 2022, Legend saw its first product approvals in U.S. and Japan (plus conditional in EU) for BCMA-targeted CAR T cell therapy Carvykti in relapsed or refractory multiple myeloma. Legend has a global partnership with Janssen, including a 50/50 profit split (70/30 in China).

Company of the Year | Insilico Medicine 

Recognizing an outstanding company in China that has made a significant impact on the landscape, reputation and ecosystem of China’s pharmaceutical, MedTech and/or healthcare industry.


Insilico Medicine 

Established in 2014, Insilico Medicine has built an end-to-end AI platform to discover targets, design drugs and predict clinical trial outcomes. The company raised a $95M Series D round in 2022 to support advancement of its internal pipeline, including a lead program in Phase I for IPF.

Woman Leader of the Year | Joan Shen, M.D., Ph.D., Founder & CEO, Neushen Therapeutics Inc.

Recognizing an outstanding female leader whose contributions have changed the landscape, reputation and ecosystem for biopharma or medtech in China.


Dr. Joan Shen

As Founder & CEO, Joan recently launched NeuShen Therapeutics with a $20M pre-Series A round to focus on AAV-based gene therapies and small molecules for neurological and psychiatric disorders. Previously, she served as CEO of I-Mab and held senior R&D roles at Janssen, Jiangsu Hengrui and Pfizer.

2021 Winners

For a list of 2021's winners, please visit the 2021 China Summit web page here.

2020 Winners

For a list of 2020’s winners, please visit the 2020 China Summit web page here.